MedElevator
Войти в исследования Drug and alcohol dependence · 2026
Sex-based effectiveness in buprenorphine/naloxone and methadone treatment for opioid use disorder: Findings from the OPTIMA trial.
СтатьяРандомизированное исследованиеМногоцентровое исследованиеPragmatic Clinical TrialНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
McAnulty Christina, Bastien Gabriel, Pek Cédric, Pelletier McCrea Tess, Bouthillier Anne, Stewart Sherry H, Socias M Eugenia, Le Foll Bernard, Jutras-Aswad Didier, OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse
Аннотация
INTRODUCTION: Opioid use disorder (OUD) is a public health challenge globally. Few studies examine sex differences in opioid agonist therapy outcomes, especially in contexts of high potency opioid consumption. Clarifying these could inform personalized treatment strategies.
METHODS: We conducted exploratory sex-stratified analyses using data from a 24-week, multicentric, pragmatic, open-label randomized controlled trial. Participants with OUD (n male=179, n female=93) were randomized to flexible take-home dosing of buprenorphine/naloxone (n male=95, n female=43) or standard methadone (n male=84, n female=50) models of care. Retention was defined as having both an active prescription and a positive urine drug screen for the assigned treatment at week 24. Opioid use was assessed as the proportion of opioid-positive urine samples. Craving was measured using the Brief Substance Craving Scale and withdrawal using the Clinical Opiate Withdrawal Scale. Substance-use-related problems were evaluated via the Addiction Severity Index (ASI).
RESULTS: In sex-stratified analyses, retention appeared overall lower for females (buprenorphine/naloxone=11.6%, methadone=26.0%) than males (buprenorphine/naloxone =28.4%, methadone=38.1%). Females showed higher opioid use overall; there was no treatment group effect on opioid use in either sex (p > 0.05). Both sexes improved in drug and psychiatric ASI domains (p < 0.05), while family-related problems improved only in males (p = 0.036). Craving decreased in both sexes, with females reporting lower craving on buprenorphine/naloxone than on methadone (p < 0.001). Withdrawal scores were higher with buprenorphine/naloxone versus methadone in males only (p = 0.026).
CONCLUSIONS: We found potential sex differences in treatment outcomes, suggesting that these may benefit from sex-based adaptations. Future research into this possibility is warranted.
METHODS: We conducted exploratory sex-stratified analyses using data from a 24-week, multicentric, pragmatic, open-label randomized controlled trial. Participants with OUD (n male=179, n female=93) were randomized to flexible take-home dosing of buprenorphine/naloxone (n male=95, n female=43) or standard methadone (n male=84, n female=50) models of care. Retention was defined as having both an active prescription and a positive urine drug screen for the assigned treatment at week 24. Opioid use was assessed as the proportion of opioid-positive urine samples. Craving was measured using the Brief Substance Craving Scale and withdrawal using the Clinical Opiate Withdrawal Scale. Substance-use-related problems were evaluated via the Addiction Severity Index (ASI).
RESULTS: In sex-stratified analyses, retention appeared overall lower for females (buprenorphine/naloxone=11.6%, methadone=26.0%) than males (buprenorphine/naloxone =28.4%, methadone=38.1%). Females showed higher opioid use overall; there was no treatment group effect on opioid use in either sex (p > 0.05). Both sexes improved in drug and psychiatric ASI domains (p < 0.05), while family-related problems improved only in males (p = 0.036). Craving decreased in both sexes, with females reporting lower craving on buprenorphine/naloxone than on methadone (p < 0.001). Withdrawal scores were higher with buprenorphine/naloxone versus methadone in males only (p = 0.026).
CONCLUSIONS: We found potential sex differences in treatment outcomes, suggesting that these may benefit from sex-based adaptations. Future research into this possibility is warranted.